Tags

Type your tag names separated by a space and hit enter

Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.EO

Abstract

INTRODUCTION

Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. Areas covered: Herein, the preclinical development and clinical data for sucroferric oxyhydroxide are reviewed, including the key data from the Phase III registration study and the latest evidence from the real-world clinical setting. Expert opinion: Sucroferric oxyhydroxide displays potent phosphate-binding capacity and clinical studies demonstrate its effectiveness for the long-term reduction of serum phosphorus levels in dialysis patients. Observational study data also show that sucroferric oxyhydroxide provides effective serum phosphorus control for hyperphosphatemic patients in the real-world clinical setting. The serum phosphorus reductions with sucroferric oxyhydroxide can be achieved with a relatively low pill burden in comparison with other phosphate binders, which may translate into better treatment adherence in clinical practice. The Phase III data also indicate that sucroferric oxyhydroxide has a favorable impact on other chronic kidney disease-related mineral bone disease parameters, including a fibroblast growth factor-23-lowering effect. Sucroferric oxyhydroxide is well tolerated and associated with low systemic iron absorption, minimizing the potential for iron accumulation or overload. These attributes render sucroferric oxyhydroxide an attractive non-calcium-containing phosphate binder for the treatment of hyperphosphatemia.

Authors+Show Affiliations

a Division of Nephrology and Hypertension , NorthShore University Health System, University of Chicago Pritzker School of Medicine , Evanston , IL , USA.b Department of Nephrology and Clinical Immunology, Division of Nephrology , RWTH University Hospital Aachen , Aachen , Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29985725

Citation

Sprague, Stuart M., and Jürgen Floege. "Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia." Expert Opinion On Pharmacotherapy, vol. 19, no. 10, 2018, pp. 1137-1148.
Sprague SM, Floege J. Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018;19(10):1137-1148.
Sprague, S. M., & Floege, J. (2018). Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opinion On Pharmacotherapy, 19(10), 1137-1148. https://doi.org/10.1080/14656566.2018.1491548
Sprague SM, Floege J. Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia. Expert Opin Pharmacother. 2018;19(10):1137-1148. PubMed PMID: 29985725.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. AU - Sprague,Stuart M, AU - Floege,Jürgen, Y1 - 2018/07/09/ PY - 2018/7/10/pubmed PY - 2018/8/29/medline PY - 2018/7/10/entrez KW - Chronic kidney disease KW - hemodialysis KW - peritoneal dialysis KW - phosphate binder KW - sucroferric oxyhydroxide SP - 1137 EP - 1148 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 19 IS - 10 N2 - INTRODUCTION: Sucroferric oxyhydroxide is a non-calcium, iron-based phosphate binder indicated for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing dialysis. Areas covered: Herein, the preclinical development and clinical data for sucroferric oxyhydroxide are reviewed, including the key data from the Phase III registration study and the latest evidence from the real-world clinical setting. Expert opinion: Sucroferric oxyhydroxide displays potent phosphate-binding capacity and clinical studies demonstrate its effectiveness for the long-term reduction of serum phosphorus levels in dialysis patients. Observational study data also show that sucroferric oxyhydroxide provides effective serum phosphorus control for hyperphosphatemic patients in the real-world clinical setting. The serum phosphorus reductions with sucroferric oxyhydroxide can be achieved with a relatively low pill burden in comparison with other phosphate binders, which may translate into better treatment adherence in clinical practice. The Phase III data also indicate that sucroferric oxyhydroxide has a favorable impact on other chronic kidney disease-related mineral bone disease parameters, including a fibroblast growth factor-23-lowering effect. Sucroferric oxyhydroxide is well tolerated and associated with low systemic iron absorption, minimizing the potential for iron accumulation or overload. These attributes render sucroferric oxyhydroxide an attractive non-calcium-containing phosphate binder for the treatment of hyperphosphatemia. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/29985725/Sucroferric_oxyhydroxide_for_the_treatment_of_hyperphosphatemia_ L2 - https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1491548 DB - PRIME DP - Unbound Medicine ER -